ASCO 2019

CytImmune is excited to announce that our collaborative work with the US National Cancer Institute has resulted in an ASCO abstract. ASCO Submission Category Developmental Therapeutics and Tumor Biology (Nonimmuno), New Targets and New Technologies Authors and Institutions Naris Nilubol, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD 208921 David Oarr and Lawrence Tamarkin,¬†…

Aurimune-TNF and T-Cells: A Surprising Result

T-Cells are all the rage these days, and with good reason. It’s hard to find an academic laboratory or big pharma company that isn’t throwing their lot behind a PDL-1 or CAR-T technology of one type or another. CytImmune is not heading down that path, but since immunotherapy in most of its current forms is…

9 is NOT enough!

AUTHOR: David Oarr In June, I traveled to Washington D.C. where I joined more than 700 pancreatic cancer patients and advocates on the Hill.¬† We met with congressmen and senators, and we collectively proclaimed that a 9 percent¬† five-year-survival rate is NOT GOOD ENOUGH. In between events and running from one congressional office to another,…

Attacking Metastatic Breast Cancer

CytImmune wants to help individuals living with metastatic breast cancer live longer and maintain a high quality of life. We hope you will support our efforts to advance our technology through a Phase II clinical trial.